Practical applications of AI across biotech commercial teams including forecasting, territory optimization, KOL targeting, and launch planning.
BioNTech Is Using AI to Build Personalised Cancer Vaccines. Here Is What Biotech Executives Need to Know. Pancreatic cancer kills over 95% of patients within five years of diagnosis. Surgery, chemotherapy, and radiation have barely moved that number in decades. But in February 2025, a small Phase 1 trial published in Nature showed something different. […]
Pfizer and BioNTech launch $3.2B AI cancer vaccine partnership Read More »
Eli Lilly’s Foundayo Gets FDA Approval. What the First No-Restriction Oral GLP-1 Means for Biotech Operators. On April 1, 2026, the FDA approved Foundayo (orforglipron), Eli Lilly’s once-daily oral GLP-1 receptor agonist for adults with obesity or overweight with at least one weight-related condition. This is not just another drug approval. It is the opening
Lilly’s Foundayo FDA approval resets the GLP-1 commercial playbook Read More »
AI Territory Optimization for Biotech Sales Teams: From Static Maps to Dynamic Intelligence AI territory optimization for biotech sales teams is one of the highest-ROI investments a commercial leader can make right now. Most biotech companies still design territories with static data, annual planning cycles, and spreadsheets built on sell-in history. In specialty pharma, that
Eli Lilly’s Foundayo Gets FDA Approval. What the First No-Restriction Oral GLP-1 Means for Biotech Operators. On April 1, 2026, the FDA approved Foundayo (orforglipron), Eli Lilly’s once-daily oral GLP-1 receptor agonist for adults with obesity or overweight with at least one weight-related condition. This is not just another drug approval. It is the opening
Lilly’s Foundayo FDA approval resets the GLP-1 commercial playbook Read More »
AI in Specialty Drug Demand Forecasting: From Missed Targets to Measurable Results AI in specialty drug demand forecasting is solving one of the most expensive problems in biotech commercial operations. Half of all pharma launches missed their first-year sales targets in 2023, according to industry analysis. For specialty drugs, the failure rate is even higher.
AI in specialty drug demand forecasting: from missed targets to measurable results Read More »
AI key account management in biotech: from relationship tracking to revenue intelligence Most biotech key account management runs on structured relationships and manual updates. Account plans are written once a quarter. CRM entries are filed after the call. Insights arrive weeks after the conversation. AI changes this. Not by replacing the account manager, but by
AI key account management in biotech: from relationship tracking to revenue intelligence Read More »
The FDA approved Foundayo (orforglipron) by Eli Lilly on April 1 2026 as a once-daily oral GLP-1 for obesity. With no food restrictions, small-molecule manufacturing, $25 monthly pricing with insurance, and a DTC launch through LillyDirect, Foundayo resets access and distribution assumptions across the entire GLP-1 market. Analysts forecast $14.79 billion in sales by 2030.
Lilly’s Foundayo FDA Approval Resets the GLP-1 Commercial Playbook Read More »
Most biotech territories are designed with static data and annual cycles. AI territory optimization delivers 10% efficiency gains, 20% more high-tier customers per rep, and reduces planning from weeks to hours.
Half of pharma launches miss first-year targets. AI models analyzing millions of data points in real time are cutting stockouts by 75%, reducing inventory costs by 55%, and delivering 80%+ forecast accuracy for specialty drugs.
AI in Specialty Drug Demand Forecasting: From Missed Targets to Measurable Results Read More »
The pharma gross-to-net bubble reached $356 billion in 2024, driven by rebates, chargebacks, and distributor fees. AI tools now enable real-time GTN monitoring, smarter distributor demand forecasting, and dynamic channel pricing. Companies adopting these approaches report 9% margin expansion and 17% better tender win rates.
How AI Closes the $356 Billion Distributor Margin Gap in Biotech Read More »
